China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes:
Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.